MedTrace Logo

A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)

NCT02479906 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2020-05-14

No results posted yet for this study

Summary

The purpose of the present study is to evaluate the safety and efficacy of Brainsway Deep TMS (DTMS) for the treatment of PTSD.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

DEVICE

Deep TMS System

Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.

DEVICE

Sham Treatment

Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions

Sponsors & Collaborators

  • Brainsway

    lead INDUSTRY

Principal Investigators

  • Moshe Isserles, MD · Hadassah Ein Karem Medical Center and Center for Addiction and Mental Health (CAMH)

  • Zafiris J. Daskalakis, MD · Center for Addiction and Mental Health (CAMH)

  • Avraham Zangen, PhD · Ben-Gurion University of the Negev

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-17
Primary Completion
2020-02-06
Completion
2020-03-31

Countries

  • United States
  • Canada
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02479906 on ClinicalTrials.gov